Opus Genetics Announces Board and Executive Changes
Ticker: IRD · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1228627
Sentiment: neutral
Topics: governance, executive-changes, board-of-directors
TL;DR
Opus Genetics shakes up its board and exec comp. Big changes coming?
AI Summary
Opus Genetics, Inc. announced on January 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key executives. This 8-K filing provides updates on the company's governance and leadership structure.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive leadership can indicate internal shifts that may affect company strategy and performance.
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- January 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Durham, NC (location) — Principal executive offices
- Ocuphire Pharma, Inc. (company) — Former company name
- REXAHN PHARMACEUTICALS, INC. (company) — Former company name
- CORPORATE ROAD SHOW DOT COM INC (company) — Former company name
FAQ
What specific roles have been affected by the departure of directors or officers?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles in this summary.
Who are the newly elected directors?
The filing mentions the election of directors but does not name them in this summary.
What are the key changes in compensatory arrangements for officers?
The filing notes adjustments to compensatory arrangements for certain officers, but the specifics are not detailed in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 17, 2025.
What is the principal executive office address for Opus Genetics, Inc.?
The principal executive office is located at 8 Davis Drive, Suite 220, Durham, NC 27709.
Filing Stats: 866 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2025-01-24 16:34:53
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IRD The Nasdaq
Filing Documents
- ef20042243_8k.htm (8-K) — 32KB
- ef20042243_ex10-1.htm (EX-10.1) — 145KB
- ef20042243_ex10-2.htm (EX-10.2) — 23KB
- 0001140361-25-001899.txt ( ) — 374KB
- ird-20250117.xsd (EX-101.SCH) — 4KB
- ird-20250117_lab.xml (EX-101.LAB) — 21KB
- ird-20250117_pre.xml (EX-101.PRE) — 16KB
- ef20042243_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In connection with the standardization of its executive employment agreements, on January 17, 2025, Opus Genetics, Inc. (the "Company") entered into an amendment and restatement (the "Magrath Amendment and Restatement") of that certain Employment Agreement with Dr. George Magrath, the Company's Chief Executive Officer, dated as of November 1, 2023 (as amended and restated, the "Magrath Employment Agreement"), and Amendment No. 2 (the "Jhaveri Amendment" and, together with the Magrath Amendment and Restatement, the "Amendments") to that certain Employment Agreement with Nirav Jhaveri, the Company's Chief Financial Officer, dated as of February 13, 2024 (as amended, the "Jhaveri Employment Agreement," and, together with the Magrath Employment Agreement, the "Employment Agreements"). The Amendments (i) increase the cash severance payments which Messrs. Magrath and Jhaveri are entitled to receive upon a qualifying termination of employment in connection with a "Change in Control" (as defined in the Employment Agreements) to the product of a severance multiple (1.5 and 1.0 for Dr. Magrath and Mr. Jhaveri, respectively) times the sum of their annual base salary and target annual bonus in effect as of the termination date and (ii) provide that, in the event of a qualifying termination of their employment in connection with a Change in Control, Messrs. Magrath and Jhaveri will be entitled to continued COBRA coverage for up to 18 months in the case of Dr. Magrath and 12 months in the case of Mr. Jhaveri. The Magrath Amendment and Restatement also amends the Magrath Employment Agreement to provide that, in the event of a qualifying termination of employment prior to a Change in Control, then in addition to the payments and benefits already described in the Magrath Employment Agreement, Dr. Magrath will also be entitl
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Amended and Restated Employment Agreement, entered into on January 17, 2025, by and between the Company and George Magrath. 10.2 Second Amendment to Employment Agreement, entered into on January 17, 2025, by and between the Company and Nirav Jhaveri. 104.1 Cover Page Interactive Data File (embedded within Inline XBRL document). *An exhibit has been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy will be furnished supplementally to the Securities and Exchange Commission upon request. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 24, 2025 OPUS GENETICS, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer